Seminars in Hematology
Volume 43 , Pages S27-S34 , April 2006

Purine Analogues in Advanced T-Cell Lymphoid Malignancies

  • Razelle Kurzrock

      Affiliations

    • Department of Bioimmunotherapy, University of Texas–M.D. Anderson Cancer Center, Houston, TX
    • Corresponding Author InformationAddress correspondence to Razelle Kurzrock, MD, Department of Bioimmunotherapy, Unit 422, University of Texas-M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030
    • ,
  • Farhad Ravandi

      Affiliations

    • Department of Leukemia, University of Texas–M.D. Anderson Cancer Center, Houston, TX

References 

  1. The Non-Hodgkin’s Lymphoma Classification Project . A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma . Blood . 1997;89:3909–3918
  2. Greer JP , Kinney MC , Loughran TP . T cell and NK cell lymphoproliferative disorders . In: Hematology (Am Soc Hematol Educ Program) . 2001;p. 259–281
  3. Jaffe ES , Harris NL , Diebold J , Muller-Hermelink HK . World Health Organization Classification of lymphomas (A work in progress) . Ann Oncol . 1998;9(suppl 5):S25–S30
  4. Foss F . Overview of cutaneous T-cell lymphoma (Prognostic factors and novel therapeutic approaches) . Leuk Lymphoma . 2003;44(suppl 3):S55–S61
  5. Diamandidou E , Cohen PR , Kurzrock R . Mycosis fungoides and Sezary syndrome . Blood . 1996;88:2385–2409
  6. Connors JM , Hsi ED , Foss FM . Lymphoma of the skin . In: Hematology (Am Soc Hematol Educ Program) . 2002;p. 263–282
  7. Sausville EA , Eddy JL , Makuch RW , Fischmann AB , Schechter GP , Matthews M , et al.   Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups . Ann Intern Med . 1988;109:372–382
  8. Bernengo MG , Quaglino P , Novelli M , Cappello N , Doveil GC , Lisa F , et al.   Prognostic factors in Sezary syndrome (A multivariate analysis of clinical, haematological and immunological features) . Ann Oncol . 1998;9:857–863
  9. Siegel RS , Pandolfino T , Guitart J , Rosen S , Kuzel TM . Primary cutaneous T-cell lymphoma (Review and current concepts) . J Clin Oncol . 2000;18:2908–2925
  10. Kaye FJ , Bunn PA , Steinberg SM , Stocker JL , Ihde DC , Fischmann AB , et al.   A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides . N Engl J Med . 1989;321:1784–1790
  11. Rosen ST , Foss FM . Chemotherapy for mycosis fungoides and the Sezary syndrome . Hematol Oncol Clin North Am . 1995;9:1109–1116
  12. Zackheim HS , Kashani-Sabet M , Amin S . Topical corticosteroids for mycosis fungoides. Experience in 79 patients . Arch Dermatol . 1998;134:949–954
  13. Dissing J , Knudsen B . Adenosine-deaminase deficiency and combined immunodeficiency syndrome . Lancet . 1972;2:1316
  14. Cabanillas F . Purine nucleoside analogs in indolent non-Hodgkin’s lymphoma . Oncology (Williston Park) . 2000;14:13–15
  15. Sandoval A , Consoli U , Plunkett W . Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes . Clin Cancer Res . 1996;2:1731–1741
  16. Seto S , Carrera CJ , Kubota M , Wasson DB , Carson DA . Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes . J Clin Invest . 1985;75:377–383
  17. Von Hoff DD , Dahlberg S , Hartstock RJ , Eyre HJ . Activity of fludarabine monophosphate in patients with advanced mycosis fungoides (A Southwest Oncology Group study) . J Natl Cancer Inst . 1990;82:1353–1355
  18. Nikko AP , RutherFord CJ , Pandya AG . Successful treatment of Sezary syndrome with lymphomatous transformation to large cell lymphoma with fludarabine phosphate . Arch Dermatol . 1996;132:978–979
  19. Kantarjian HM , Redman JR , Keating MJ . Fludarabine phosphate therapy in other lymphoid malignancies . Semin Oncol . 1990;17:66–70
  20. Foss FM , Ihde DC , Linnoila IR , Fischmann AB , Schechter GP , Cotelingam JD , et al.   Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome . J Clin Oncol . 1994;12:2051–2059
  21. Scarisbrick JJ , Child FJ , Clift A , Sabroe R , Whittaker SJ , Spittle M , et al.   A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma . Br J Dermatol . 2001;144:1010–1015
  22. Bellosillo B , Villamor N , Colomer D , Pons G , Montserrat E , Gil J . In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia . Blood . 1999;94:2836–2843
  23. Quaglino P , Fierro MT , Rossotto GL , Savoia P , Bernengo MG . Treatment of advanced mycosis fungoides/Sezary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy . Br J Dermatol . 2004;150:327–336
  24. Grever MR , Siaw MF , Jacob WF , Neidhart JA , Miser JS , Coleman MS , et al.   The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy . Blood . 1981;57:406–417
  25. Grever MR , Bisaccia E , Scarborough DA , Metz EN , Neidhart JA . An investigation of 2′-deoxycoformycin in the treatment of cutaneous T-cell lymphoma . Blood . 1983;61:279–282
  26. Cummings FJ , Kim K , Neiman RS , Comis RL , Oken MM , Weitzman SA , et al.   Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease . J Clin Oncol . 1991;9:565–571
  27. Ho AD , Thaler J , Willemze R , Lauria F , Mandelli F , Stryckmans P , et al.   Pentostatin (2′-deoxycoformycin) for the treatment of lymphoid neoplasms . Cancer Treat Rev . 1990;17:213–215
  28. Ho AD , Suciu S , Stryckmans P , De Cataldo F , Willemze R , Thaler J , et al.   Pentostatin in T-cell malignancies—A phase II trial of the EORTC Leukemia Cooperative Group . Ann Oncol . 1999;10:1493–1498
  29. Greiner D , Olsen EA , Petroni G . Pentostatin (2′-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma . J Am Acad Dermatol . 1997;36:950–955
  30. Grever MR , Leiby JM , Kraut EH , Wilson HE , Neidhart JA , Wall RL , et al.   Low-dose deoxycoformycin in lymphoid malignancy . J Clin Oncol . 1985;3:1196–1201
  31. Mercieca J , Matutes E , Dearden C , MacLennan K , Catovsky D . The role of pentostatin in the treatment of T-cell malignancies (Analysis of response rate in 145 patients according to disease subtype) . J Clin Oncol . 1994;12:2588–2593
  32. Dearden C , Matutes E , Catovsky D . Deoxycoformycin in the treatment of mature T-cell leukaemias . Br J Cancer . 1991;64:903–906
  33. Kurzrock R , Pilat S , Duvic M . Pentostatin therapy of T-cell lymphomas with cutaneous manifestations . J Clin Oncol . 1999;17:3117–3121
  34. Tsimberidou AM , Giles F , Duvic M , Fayad L , Kurzrock R . Phase II study of pentostatin in advanced T-cell lymphoid malignancies (Update of an M.D. Anderson Cancer Center series) . Cancer . 2004;100:342–349
  35. Braiteh F , Ng C , Kurzrock R . Refractory Hodgkin’s lymphoma responds to pentostatin (2′ deoxycoformycin) . Leuk Lymphoma . 2006;47:373–375
  36. Foss FM , Ihde DC , Breneman DL , Phelps RM , Fischmann AB , Schechter GP , et al.   Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome . J Clin Oncol . 1992;10:1907–1913
  37. Saven A , Carrera CJ , Carson DA , Beutler E , Piro LD . 2-Chlorodeoxyadenosine (An active agent in the treatment of cutaneous T-cell lymphoma) . Blood . 1992;80:587–592
  38. O’Brien S , Kurzrock R , Duvic M , Kantarjian H , Stass S , Robertson LE , et al.   2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders . Blood . 1994;84:733–738
  39. Kuzel TM , Hurria A , Samuelson E , Tallman MS , Roenigk HH , Rademaker AW , et al.   Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma . Blood . 1996;87:906–911
  40. Ravandi F , O’Brien S . Infections associated with purine analogs and monoclonal antibodies . Blood Rev . 2005;19:253–273
  41. Tam CS , Wolf MM , Januszewicz EH , Grigg AP , Prince HM , Westerman D , et al.   A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies . Cancer . 2004;101:2042–2049
  42. Ravandi F , O’Brien S . Alemtuzumab . Expert Rev Anticancer Ther . 2005;5:39–51
  43. Dearden CE , Matutes E , Cazin B , Tjonnfjord GE , Parreira A , Nomdedeu B , et al.   High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H . Blood . 2001;98:1721–1726
  44. Gautschi O , Blumenthal N , Streit M , Solenthaler M , Hunziker T , Zenhausern R . Successful treatment of chemotherapy-refractory Sezary syndrome with alemtuzumab (Campath-1H) . Eur J Haematol . 2004;72:61–63
  45. Kennedy GA , Seymour JF , Wolf M , Januszewicz H , Davison J , McCormack C , et al.   Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab . Eur J Haematol . 2003;71:250–256
  46. Lundin J , Hagberg H , Repp R , Cavallin-Stahl E , Freden S , Juliusson G , et al.   Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome . Blood . 2003;101:4267–4272
  47. Ginaldi L , De Martinis M , Matutes E , Farahat N , Morilla R , Dyer MJ , et al.   Levels of expression of CD52 in normal and leukemic B and T cells (Correlation with in vivo therapeutic responses to Campath-1H) . Leuk Res . 1998;22:185–191
  48. Ravandi F , Faderl S . Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin . Leuk Res . 2006;30:103–105
  49. Rook AH , Kuzel TM , Olsen EA . Cytokine therapy of cutaneous T-cell lymphoma (Interferons, interleukin-12, and interleukin-2) . Hematol Oncol Clin North Am . 2003;17:1435–1448
  50. Marolleau JP , Baccard M , Flageul B , Rybojad M , Laroche L , Verola O , et al.   High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma . Arch Dermatol . 1995;131:574–579
  51. Piekarz RL , Robey R , Sandor V , Bakke S , Wilson WH , Dahmoush L , et al.   Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma (A case report) . Blood . 2001;98:2865–2868
  52. Knox S , Hoppe RT , Maloney D , Gibbs I , Fowler S , Marquez C , et al.   Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody . Blood . 1996;87:893–899

PII: S0037-1963(05)00267-2

doi: 10.1053/j.seminhematol.2005.12.010

Seminars in Hematology
Volume 43 , Pages S27-S34 , April 2006

Article Tools

* Image Usage & Resolution